GRANULOMATOSIS WITH POLYANGIITIS
Clinical trials for GRANULOMATOSIS WITH POLYANGIITIS explained in plain language.
Never miss a new study
Get alerted when new GRANULOMATOSIS WITH POLYANGIITIS trials appear
Sign up with your email to follow new studies for GRANULOMATOSIS WITH POLYANGIITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a dengue vaccine be safe for autoimmune patients? new trial aims to find out
⭐️ VACCINE ⭐️ Recruiting nowThis study tests whether the Butantan-Dengue vaccine is safe and works well in people aged 12–59 with autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are stable on low or no immune-suppressing drugs. Participants receive one vaccine dose and are monitored f…
Matched conditions: GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:07 UTC
-
New drug avacopan under Long-Term safety review for vasculitis patients
Disease control Recruiting nowThis study is checking the long-term safety of a drug called avacopan for people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. About 300 adults who need treatment for a new diagnosis or flare-up will take avacopan or a placebo. The…
Matched conditions: GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE4 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental liquid drug tested in ventilator patients with rare lung bleeding disease
Disease control Recruiting nowThis early study tests whether a liquid form of the drug avacopan can be safely given through a feeding tube to critically ill patients with ANCA vasculitis who have severe lung bleeding and need a ventilator. The main goal is to measure how the drug levels change in the blood ov…
Matched conditions: GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for rare vasculitis: Three-Drug trial targets Non-Responders
Disease control Recruiting nowThis phase 3 trial is for people with granulomatosis with polyangiitis (GPA), a rare autoimmune disease causing blood vessel inflammation, who did not get better with standard treatments. It compares three salvage therapies: rituximab plus another drug, tocilizumab, or tofacitini…
Matched conditions: GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for Wegener's patients: drug aims to stop flare-ups
Disease control Recruiting nowThis study tests a drug called obinutuzumab in 33 adults with a relapsing form of granulomatosis with polyangiitis (GPA, formerly Wegener's). The goal is to see if the drug can stop disease activity and turn off the related antibody. Participants will be followed for 6 months to …
Matched conditions: GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Could a 4-Week steroid course be safer for vasculitis patients?
Disease control Recruiting nowThis phase 3 trial is testing whether a 4-week low-dose steroid regimen, given alongside standard drugs like rituximab or cyclophosphamide, is safer and as effective as the usual longer steroid treatment for ANCA vasculitis with severe kidney problems. The study will enroll 36 pe…
Matched conditions: GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE3 • Sponsor: Ottawa Hospital Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC